With an overall five-year survival rate of less than 10 percent, pancreatic cancer is one of the deadliest forms of this disease. Pancreatic cancer prognosis and survival rates, however, will vary based on the stage at diagnosis and the effectiveness of any treatments undertaken. Unfortunately, this form of cancer is often only detected in its later stages, which gives rise to such a high mortality rate. According to the American Cancer Society, about 53,000 people across the country will be diagnosed with this disease in the coming year. An estimated 43,000 will die pancreatic cancer-related deaths.
The specific pancreatic cancer prognosis a patient may receive will depend on the stage of the disease in which detection occurs and other related factors. As it is with all forms of cancer, survivability tends to be higher when the disease is caught in earlier stages when interventions have a higher chance of being successful. The cancer society estimates these five-year survival rates based on stage of diagnosis:
- Stage IA – About 14 percent
- Stage IB – About 12 percent
- Stage IIA – About 7 percent
- Stage IIB – About 5 percent
- Stage III – About 3 percent
- Stage IV – about 1 percent
The survival rates are estimates, however. An individual’s prognosis may vary based on the nature of the tumor, its response to treatment and other case-specific factors.
Researchers are working with intensity to develop better treatments for this form of cancer and more effective screening tools. In the meantime, it is recommended those at risk take steps to lower their likelihood of developing this disease. Common risk factors include obesity, tobacco use, age, family history, certain genetic syndromes, new-onset type 2 diabetes and chronic pancreatitis, among others. People who are at risk for the disease are urged to talk to their doctors about steps they can take to help prevent the disease.
Pancreatic cancer is projected to strike more than 53,000 Americans in the coming year. An estimated 43,000 will die from the disease, making it one of the deadliest forms of cancer in the United States. Understanding the symptoms and risks, however, can help people gain access to earlier intervention, which could lead to life-preserving treatments.
Pancreatic cancer is known to be especially deadly because this disease is often only detected in later stages. This is because symptoms at the earliest stages tend to be rather vague, if they present at all. The most common symptoms include:
- A darkening of the urine
- Light-colored stools or greasy stools
- Itchy skin
- Back or abdominal pain
- Unexplained weight loss
- Vomiting and nausea
- Liver or gallbladder enlargement
- Now-onset type 2 Diabetes
Since many of these symptoms are associated with a host of other conditions, pancreatic cancer may go undetected for a long period of time. That is why understanding personal risk factors may also be important to help lead to an earlier diagnosis. Risks include smoking, obesity, new-onset diabetes, family history, chronic pancreatitis and certain genetic syndromes, among others. When symptoms appear in people at higher risk for this disease, doctors may recommend screening.
Pancreatic cancer has several different stages the disease may progress through. They are:
- Stage 0 – At this stage, the tumor is generally confined to the top layers of the duct cells.
- Stage IA – This stage of tumor is confined to the pancreas itself and is 2 cm across or less.
- Stage IB – At this point, a tumor will measure to more than 2 cm across, but will not have spread to nearby lymph nodes or distant sites.
- Stage IIA – Tumors at this stage have grown outside the pancreas, but have not spread to major blood vessels, nerves or nearby lymph nodes.
- Stage IIB – The tumor at this stage can be confined to the pancreas or outside it, but will not affect major blood vessels or nerve. Spread to nearby lymph nodes, however, will have occurred.
- Stage III – Tumors at this stage have grown outside the pancreas and into nearby major blood vessels or nerves. Cancer may or may not have spread to nearby lymph nodes.
- Stage IV – Cancer at this stage will affect distant sites in addition to the pancreas and nearby tissue.
People who are concerned about pancreatic cancer are urged to talk to their doctors. Understanding personal risks and symptoms can help lead to a more rapid diagnosis should the disease present.
Pancreatic cancer is a notorious killer. Associated with a one-year survival rate that is dismally low and a five-year survival rate of less than 10 percent, a positive diagnosis of this condition is often a death sentence. While researchers are well aware of several factors that combine to make this form of cancer so very deadly, an understanding of why it tends to be so aggressive has been largely elusive. A new study sheds light on a possible causation.
The study in question found that pancreatic cancer tumors active a factor known as Zeb1. This factor controls how cells survive in their early stages of development. When cells are fully developed, Zeb1 is typically blocked. If the factor is reactivated in cancer cells, however, it allows these malignant cells to quickly disseminate throughout the body, essentially paving the way for secondary tumor formation.
The full implications of the finding aren’t clear yet, but researchers hope the discovery of the Zeb1 factor in pancreatic cancer may lead to more effective treatment strategies down the road. If this factor’s activation can be reversed or blocked entirely, the aggressiveness of tumors might be an addressable factor.
Pancreatic cancer is expected to strike more than 53,000 Americans this year. More than 40,000 people will die from this cause. With very few, if any, symptoms at its onset and no screening tool available for widespread use, this form of cancer is often diagnosed in later stage. This makes it very difficult to treat, as evidence by the low survival rate. People who are at risk for this form of cancer are urged to report any unusual symptoms to their healthcare providers. Risk factors include new-onset diabetes, obesity, family history, smoking and chronic pancreatitis, among others. People who are concerned about their risks for pancreatic cancer are urged to talk to their doctors. Addressing the risks that can be changed is highly advised.
More than 53,000 Americans will be diagnosed with pancreatic cancer in the coming year. An estimated 43,000 people will die from this cause. With a five-year survival rate of less than 10 percent, this form of cancer is widely considered one of the deadliest. Lacking a viable early screening test for widespread use, this type of cancer is hard to detect and especially difficult to treat. Those facts make understanding personal risk and the signs to look for critical.
Pancreatic cancer tends to develop unchecked in its earliest phases because it may present with no or very vague symptoms. Understanding what those vague symptoms are, however, can lead to earlier diagnosis and the potential for more successful treatment.
Some of the more common signs of pancreatic cancer include:
- Jaundice – A yellowing of the eyes and the skin can be caused by a pancreatic tumor blocking off a bile duct. This causes bile to build up and may result in changes in skin coloration, darker urine and light-colored stools.
- Abdominal pain – Persistent pain in the abdomen or back may indicate a pancreatic tumor.
- Sudden, unexplained weight loss – If a fair amount of weight is lost for no particular reason, it may be caused by inhibition of digestive enzymes.
- Diabetes – Newly diagnosed type two diabetes may be caused by a pancreatic tumor.
- Blood clots – Pancreatic cancer is associated with the production of deep vein thrombosis, or blood clotting.
While the more common symptoms of pancreatic cancer are also strongly linked to other conditions, knowing what they are can prove critical. When these symptoms combine with personal risk factors, they may signal a need to screen for the presence of pancreatic cancer. Some of the more common risks for pancreatic cancer include obesity, smoking, family history, chronic pancreatitis and diabetes, among others.
People who are concerned about pancreatic cancer are urged to talk with their doctors about personal risks. Should symptoms arise, it is important to seek medical care.
With a five-year survival rate that’s already less than 10 percent, pancreatic cancer is considered among the deadliest forms of this disease known to man. For those who smoke, a diagnosis of pancreatic cancer may pose an even higher mortality risk, researchers say.
A recent study that looked into the links between smoking and pancreatic cancer death risks revealed very disturbing findings. Smokers, researchers say, witnessed a 40 percent reduction in survival likelihood versus their counterparts who had never smoked.
To arrive at their findings, researchers dove into data related to smoking status and more than 1,000 pancreatic cancer patients from the United States. Researchers say the data showed that smokers had a 37 percent increased risk of death overall. The driving factor behind the mortality rate, researchers believe, is partially attributed to high levels of cotinine, a metabolite of nicotine. Researchers noted there was no reduction in survival rate for former smokers, which means quitting may make a big difference on this front.
Pancreatic cancer is expected to strike an estimated 53,000 Americans in the coming year. About 43,000 people die from this causation each year in the United States. The disease has no widely available early screening tool and is known to be highly resistant to standard forms of therapy. Considering that most cases are diagnosed in later stages, the overall survival rate for pancreatic cancer is extremely low. Researchers, however, say that quitting smoking or avoiding it all together could have an impact on an individual patient’s outcome should this disease develop.
Pancreatic cancer is associated with a long list of risk factors, some changeable and some not. Smoking happens to be one of the risks that people can eliminate. New onset diabetes, obesity, chronic pancreatitis and family history may also elevate risks. People who are concerned about pancreatic cancer are urged to talk to their doctors. If smoking is a concern, healthcare providers can assist with cessation advice.
With a five-year survival rate that’s less than 10 percent, pancreatic cancer is considered one of the most difficult forms of this disease to treat. Often diagnosed in later stages, this form of cancer is noted for having tumors that simply do not respond to common treatments, such as chemotherapy. Researchers, however, believe they may have uncovered a way to produce more positive results through treatment. The method involves taking a two-step approach to chemotherapy.
A recent study was conducted to determine if a more in-depth approach to chemotherapy would have an impact on results. The treatment involved the use of Fasudil, a drug used on stroke victims, for a three-day period. Researchers believed the drug might prepare tumors to be more receptive to standard chemotherapy. Once the course of Fasudil was completed, chemotherapy began.
The results of the small-scale trial were quite promising. Researchers found that the two-step treatment was able to double survival time while impeding the spread of cancer. The trial was conducted on mice and using tumor samples from human patients, as well.
While more work needs to be done to determine if the approach would be beneficial for more widespread use, researchers say it is a positive step forward. Clinical trials to test safety for patient use are planned and the off-patent Fasudil, scientists say, is ripe for repurposing for uses such as fighting pancreatic cancer.
It is estimated that more than 53,000 Americans will be diagnosed with pancreatic cancer in the coming year. An estimated 43,000 will die from this cause. With no early screening test widely available and few symptoms, if any, at its onset, pancreatic cancer remains a very difficult form of the disease to detect and treat. The latest research into a two-step approach may someday help make treatment more effective. In the meantime, people at risk for this condition are strongly urged to talk to their healthcare providers.
A link between potentially deadly pancreatic cancer and new onset diabetes has long been known. While the two conditions don’t always go hand-in-hand, the frequency rate has been enough for researchers to begin probing the connection between pancreatic cancer and the rare type 3c diabetes. A recent study has shed light on a biomarker that may someday lead to earlier detection and lifesaving treatment in diabetics who also happen to have pancreatic cancer.
In studying the connection between the two conditions, researchers found a hormone called Neuromedin U. This hormone decreases insulin levels in the body, essentially creating diabetic symptoms. Researchers have found that Neuromedin U is not typically created in the pancreas. It is believed to instead be produced and secreted into the blood by cells associated with early-stage pancreatic cancer.
The recent study is especially encouraging for a few important reasons. Firstly, the hormone may hold the key as to why people who are not obese present with diabetes later in life and are also estimated to be 20-fold more likely to develop pancreatic cancer within a short period after diabetes diagnosis. Secondly, the hormone may serve as a way for researchers to develop a tool for early detection of pancreatic cancer. This, in turn, could result in much more positive outcomes for patients with this disease.
The American Cancer Society estimates that some 53,000 people in the U.S. will be diagnosed with pancreatic cancer in the coming year. About 43,000 people will die from the cause in the next year alone. Very difficult to detect when it is in its earlier stages and nearly impossible to treat in later stages, pancreatic cancer is considered one of the deadliest form of the disease. The hormone Neuromedin U may someday soon serve as a way to open the door to earlier detection and more successful treatment.
Transforming pancreatic cancer from one of the deadliest forms of this disease into a less terrifying prospect is the focus of much study as of late. With a five-year survival rate at present that is less than 10 percent, much work remains to be done. According to the American Cancer Society, about 53,000 people in the U.S. are diagnosed each year. An estimated 43,000 die from the cause. Developing a reliable, accurate tool for early detection, many experts say, could push those numbers in a much more positive direction.
As it stands currently, pancreatic cancer is an extremely difficult disease to detected. This is partially due to the location of the pancreas deep inside the body. This fact is complicated by the reality that pancreatic cancer tends to present with no symptoms initially. If symptoms are present, they tend to be very vague and quite easy to link to a long list of other possible causes.
While a reliable tool for early screening like those used for prostate and breast cancer is not yet available, this prospect is the focus of much research. One ongoing study involves the use of a blood test that is able to detect biomarkers that have been linked to pancreatic cancer. This detection tool was able to find early stage pancreatic cancer in a whopping 90 percent of patients who took part in a recent pilot study. That study, however, included fewer than 60 patients. Although still a way off from being green lighted for more widespread use, the blood test could be a game changer in the detection and treatment of pancreatic cancer.
People who are at risk for the development of pancreatic cancer are urged to speak with their doctors about prevention and symptoms to watch for. Early detection of this form of cancer is considered critical for improving the potential for a positive outcome.
Each year, almost as many people who are diagnosed with pancreatic cancer in the United States die from the disease. The American Cancer Society estimates about 53,000 Americans will be diagnosed with this form of cancer in the coming year. Some 43,000 will lose their life. A disease that strikes men and women alike, pancreatic cancer’s grim survival statistics are largely associated with difficulty in detecting the condition in its earlier stages and a lack of effective treatment to halt its growth.
Researchers believe they may have found a way to better manage pancreatic cancer after it forms. Their works involves a protein known as S100P. This protein is known to overexpress when pancreatic cancer is present, working to signal changes in the body that promote the growth and spread of cancer cells. To change this, researchers have created a compound that may stop S100P from activating. This, in turn, could slow or halt the development of pancreatic cancer. A total of nearly 20 possible drugs have been identified that may prevent pancreatic cancer cells from migrating.
Although still very much in the testing phases, this line of research is offering great hope for the eventual treatment of pancreatic cancer. This line of work to slow growth and stop spread comes as other researchers are diligently testing possible early screening procedures. Success in both arenas could have a very strong and positive impact on the grim numbers currently associated with pancreatic cancer.
Pancreatic cancer is considered rare, but its high mortality rate makes it a very big concern for doctors and patients alike. People at high risk for the development of this form of cancer are urged to speak with their healthcare providers about cutting risks that can be addressed. New onset diabetes, chronic pancreatitis, family history, tobacco use and obesity are all potential risk factors.
Pancreatic cancer has one of the grimmest survival rates of all forms of this disease in the United States. It is estimated that some 53,000 Americans will be diagnosed with this form of cancer in the coming year. About 43,000 people will lose their lives to this cause.
Researchers are hoping a new breakthrough in early screening technology may soon turn those numbers in a positive direction. The breakthrough in question is a simple blood test that is showing promise in being able to detect pancreatic cancer in its earlier, more treatable stages.
Although still very much under study, the blood test is showing much promise. It focuses in on a particular protein in the blood that tends to over express when pancreatic tumors are present. Researchers have developed a biosensor that enables them to quantify the amount of this protein in the blood to see if pancreatic cancer is likely present. A recent pilot study was conducted to test the viability. The study included a group of healthy people and a sampling of patients confirmed to have pancreatic cancer at varying stages. People with chronic inflammation of the pancreas were also included. The results showed the biosensor was able to successfully identify people with pancreatic cancer, even those in earlier stages of the disease.
While it could still be some time before this test is widely available, the pilot study has paved the way for a larger clinical trial. How soon those results might be available remains unclear.
Pancreatic cancer is considered one of the deadliest forms of cancer. Clinicians have long held that might not be the case if an easier, more accurate way to detect this condition in early stages was available. Whether the new blood test will prove to be that remains to be seen. The pilot study, however, has created great hope that someday soon pancreatic cancer might be more readily treatable courtesy of earlier detection techniques.